Laboratory (LAB)

CHTMAD – SGI – Information Management Service (IMS)

N. Reference

SGI-2023-021

Author: CHTMAD - Victor Costa

Project Expanding Digital Health through a pan-European EHRxF-based Ecosystem

Vila Real, October 23rd, 2023

Version v2 - CHTMAD - 24-10-2023 14:21


TABLE OF CONTENTS

1	INTE	EGRATION DIAGRAMS	4
2	Mes	ssages & Events	5
	2.1	Events Used	5
3	Segi	ments	
	3.1	MSH – Message Header Segment	6
	3.2	PID – Patient Identification Segment	
	3.3	PV1 – Patient Visit Segment	
	3.4	MSA – Message Acknowledgement Segment	
	3.5	ORC – Common Order Segment	
	3.6	OBR – Observation Request Segment	
	3.7	SCH – Schedule Activity Information Segment	
	3.8	OBX – Observation/Result Segment	
	3.9	AlL – Appointment Information – Location Segment	
	3.10	NTE – Notes and Comments	
4		mples	
	4.1	Request analytics (Clinidata receives)	9
	4.2	Create samples (Clinidata receives)	
	4.3	Cancel scans (Clinidata receives)	9
	4.4	Admission/Effectiveness (Clinidata reœive)	9
	4.5	Collection done (Clinidata receives)	10
	4.6	Exam Processing (Clinidata Sends)	10
	4.7	Creating Analyses	10
	4.8	Cancellation of Analyses	10
	4.9	Scheduling	10
	4.10	Reschedule	10
	4.11	Appointment Cancellation	11
	4.12	Admission/Effectiveness	11
	4.13	Sample	11
	4.14	Cancellation of Analyses	11
	4.15	Validated Analysis Report	11
	4.16	Analysis in Processing	11
	4.17	Simple analytical results	11
	4.18	Analytical Results with Microorganisms	12
	4.19	Sample Return with label	12
	4.20	Sending the PDF with the Results	12
	4.21	Disabling Scans	12

| TECHNICAL SPECIFICATION – LIS - CHTMAD

	4.22	Enabling Analytics	.12
	4.23	Insertion of Analyses	.13
	4.24	Analytics Update	.13
5	Refe	erences and actions	.13

1 INTEGRATION DIAGRAMS



2 MESSAGES & EVENTS

Value	Description
OML	Laboratory Order Message
IUS	Schedule Information Unsolicited Message
ORU	Unsolicited Transmission of an Observation Message

Table 1 - Messages Used

2.1 EVENTS USED

Value	Description
OML^O21	OML Laboratory Order Trigger Event
SIU^S12	Notification of new appointment booking
SIU^S14	Notification of appointment rescheduling
SIU^S15	Notification of appointment cancellation
ORU^R01	ORU Subscription
ORR^022	Application Acknowledgement to an OML message

Table 2 - Events Used

3 SEGMENTS

In each segment table, fields and attributes are defined that are specified by the following abbreviations:

SEQ – Sequence number in the segment

LEN – Field size

DT - Type data

OPT – obligations

- R Mandatory
- O Optional
- C Conditional (depends on the type of event or another field)
- X Not used in the event
- B- Maintained only for backward compatibility reasons with other versions HL7
- W retired

RP/# - Multiplicity

- Y Can be repeated
- Y/N Can be repeated up to a maximum of N times

3.1 MSH - MESSAGE HEADER SEGMENT

The MSH segment defines the type, source, and destination of the message, as well as some specific details regarding the syntax.

SEQ	LEN	DT	OPT	RP/ #	DESCRIPTION	EXPECTED VALUE	
1	1	ST	R		Field Separator	View Delimiters and Separators (1.3.2)	
2	4	ST	R		Encoding Characters	View Delimiters and Separators (1.3.2)	
3	227	HD	R		Sending Application	Source Application	
4	227	HD	R		Sending Facility	Source Installation Location	
5	227	HD	R		Receiving Application	tion Target Application	
6	227	HD	R		Receiving Facility	Target Installation Location	
7	26	TS	R		Date/Time Of Message	Date/Time the message was sent <yyyymmddhhmmss></yyyymmddhhmmss>	
9	15	.MSG	R		Message Type	Message Type <>^ <event type="">. See table of Message Types and Event Types</event>	
10	20	ST	R		Message Control ID	A value that uniquely identifies the message. This value is returned in the MSA segment	
11	3	EN	R		Processing ID	Processing Mode T: Testing, P: Production, ,	
12	60	VID	R		Version ID	2.5	

Table 3 – Segment MSH

3.2 PID-PATIENT IDENTIFICATION SEGMENT

The PID segment is used to define patient, personal, and demographic information.

SEQ	LEN	DT	OPT	RP/#	DESCRIPTION	EXPECTED VALUE
1	4	ONESELF	R		Set ID - PID	1
3	250	CX	R	Υ	Patient Identifier List	<patient entity="" identifier="" in="" requesting="" the="">^<patient identifier in the destination entity>^<patient card="" number=""></patient></patient </patient>
5	250	XPN	R	Υ	Patient Name	<sumame>^<first name="">^<other names=""></other></first></sumame>
7	26	TS	Or		Date/Time of Birth	Date/Time of Birth <yyyymmddhhmmss></yyyymmddhhmmss>
8	1	IS	Or		Administrative Sex	Patient Gender M: Male F: Female O: Other
18	250	CX	R		Patient Account Number	<patient case="" number=""></patient>

Table 4 - PID Segment

3.3 PV1 - PATIENT VISIT SEGMENT

The PV1 segment is used to communicate information about the patient's visit.

SEQ	LEN	DT	OPT	RP/#	DESCRIPTION	EXPECTED VALUE
1	4	ONESELF	R		Set ID - PV1	1
2	1	IS	R		Patient Class	Episode Type Identifies the source. It can always come U.
3	80	.PL	С		Assigned Patient Location	<patient's origin="">^<room>^<bed>^<institution></institution></bed></room></patient's>
19	16	ST	С		Visit Number	Episode number

Table 5 - PV1 Segment

3.4 MSA – MESSAGE ACKNOWLEDGEMENT SEGMENT

The MSA segment is used as the response (success or error) to be sent to the issuer.

SEQ	LEN	DT	OPT	 DESCRIPTION	EXPECTED VALUE
1	2	ID	R	Acknowledgment Code	Original Mode: AA: Accept AE: Error AR: Reject
2	20	ST	R	 Message Control ID	The value obtained in MSH-10
3	80	ST	В	Text Message	Error message

Table 6 - MAS Segment

3.5 ORC - COMMON ORDER SEGMENT

The ORC segment is used to transmit information that is common to all orders.

SEQ	LEN	DT	OPT	RP/ #	DESCRIPTION	EXPECTED VALUE
1	2	ID	R		Order Control	NW Segment Role: New CA Request: Cancel RE Request: Report
2	22	HEY	С		Placer Order Number	Unique identifier of the requisition in the requesting entity <requisition id="">^<requester></requester></requisition>
3	22	HEY	С		Filler Order Number	Unique identifier of the request in the executing entity <id_requisição>^<destination></destination></id_requisição>
4	22	HEY	R		Placer Group Number	Identifier of the service in the requesting entity
9	26	TS	R		Date/Time of Transaction	Current date
12	250	XCN	Or	Υ	Ordering Provider	<referring id="" physician="">^<requesting name="" physician=""></requesting></referring>

Table 7 - ORC Segment

3.6 OBR - OBSERVATION REQUEST SEGMENT

The OBR segment allows the sending of specific information for the performance of the exam (Type of Exam, Clinical Information, etc.).

SEQ	LEN	DT	OPT	RP/#	DESCRIPTION	EXPECTED VALUE
1	4	ONESELF	Or		Set ID – OBR	Sequence number
2	22	HEY	С		Placer Order Number	Accession Number of the requesting entity <accession number="">^<requester></requester></accession>
3	22	HEY	С		Filler Order Number *	Destination entity Accession Number <accession number="">^<destination></destination></accession>
4	250	EC	R		Universal Service Identifier	Required exam <exam id="">^<description></description></exam>
6	26	TS	Or		Requested Date/Time	Attendance creation date
16	250	XCN	С	Υ	Ordering Provider	<referring id="" physician="">^<requesting name="" physician=""></requesting></referring>

Table 8 - OBR Segment

3.7 SCH-SCHEDULE ACTIVITY INFORMATION SEGMENT

The SCH segment contains information about the exam appointment.

SEQ	LEN	DT	OPT	RP/ #	DESCRIPTION	EXPECTED VALUE
1	75	HEY	С		Placer Appointment ID	Unique identifier of the requisition in the requesting entity <requisition id="">^<requester></requester></requisition>
2	75	HEY	С		Filler Appointment ID	Unique identifier of the request in the executing entity <id_requisição>^<destination></destination></id_requisição>
4	22	HEY	R		Placer Group Number	Request Identifier in bHealth - Analysis Grouping
6	250	EC	R		Event Reason	Reason for the event (for SIU^S15 only)
25	250	EC	Or	Υ	Filler Status Code	<unique code="" exam="">^<exam description=""></exam></unique>
26	22	HEY	С	Υ	Placer Order Number	Unique identifier of the requisition in the requesting entity <requisition id="">^<requester></requester></requisition>
27	22	HEY	С	Υ	Filler Order Number	Unique identifier of the request in the executing entity <id_requisição>^<destination></destination></id_requisição>

Table 9 - SCH Segment

3.8 OBX - OBSERVATION/RESULT SEGMENT

This segment is used to send details of the observation (Report).

SEQ	LEN	DT	OPT	RP/#	DESCRIPTION	EXPECTED VALUE
1	4	ONESELF	Or		Set ID – OBX	Sequence number
2	2	ID	С		Value Type	Data type 'NM' if numeric, remaining 'FT'
3	250	EC	R		Observation Identifier	<heading code="">^<heading name="">^<heading identifier=""></heading></heading></heading>
5	65536	TX	С		Observation Value	Report (text). RTF or plain text
6	250	EC	Or		Units	Unit
7	60	ST	Or		References Range	Reference values
8	5	IS	Or	Υ	Abnormal Flags	Limits of Results
11	1	ID	R		Observation Result Status	Observation Status P: Preliminary C: Correction F: Final
14	26	TS	Or		Date/Time of the Observation	Date of attendance
16	250	XCN	С	Υ	Responsible Observer	In the user who validated>^ Aname of the user who validated>

Table 10 - OBX Segment

3.9 AIL – APPOINTMENT INFORMATION – LOCATION SEGMENT

The AIL segment is used to send the description of the locations that were requested for the event.

SEQ	LEN	DT	OPT	RP/#	DESCRIPTION	EXPECTED VALUE
1	4	ONESELF	R		Set ID – AIL	Sequence number
2	3	ID	R		Segment Action Code	Fixed value 'D' - Delete/'U' - Update/'A' - Add
3	80	.PL	С		Location Resource ID	^^^^^^^ <exam description="" location="">^<unique code="" location="">&<location name="">^</location></unique></exam>
6	26	TS	R		Start Date/Time	Exam Appointment Date/Time <yyyymmddhhmmss></yyyymmddhhmmss>
9	20	NM	Or		Duration	Exam duration in minutes
10	250	EC	Or		Duration Units	М

Table 11 - AIL Segment

3.10 NTE - NOTES AND COMMENTS

This segment is used to send notes and comments regarding the order taken.

SEQ	LEN	DT	OPT	RP/#	DESCRIPTION	EXPECTED VALUE
1	4	ONESELF	R		Set ID - NTE	Sequence number
3	65536	FT	С	Υ	Comment	Comment
4	250	EC	С		Comment Type	<question name="">^<question id=""></question></question>

Table 12 - NTE Segment

4 EXEMPLES

Sample messages

4.1 REQUEST ANALYTICS (CLINIDATA RECEIVES)

4.2 CREATE SAMPLES (CLINIDATA RECEIVES)

4.3 CANCEL SCANS (CLINIDATA RECEIVES)

4.4 ADMISSION/EFFECTIVENESS (CLINIDATA RECEIVE)

```
ORC|SC|0478561-01^BHEALTH|^CLINIDATA|0478561|IP|||20220923113011||27837^ASUNCION
III.
SPM|1|||GEN^Product gen\XE9\rich||||||
4.5
   COLLECTION DONE (CLINIDATA RECEIVES)
BP3||180001010000000|||||||ext||||||||||||||||||^^20231018124908
4.6
   EXAM PROCESSING (CLINIDATA SENDS)
MSH| ^~\& | LABENTERPRISE | CHTMAD | LABENTERPRISEB | CHTMAD | 20230915162915 | | OML^021^0ML_021 | 4680 | P | 2.5 | | | ALPID | 1 | 187139^^^SPMS^
NS||A^TEST^^^^L||19870612000000|M|||||||13003304^^^SPMSPV1|1|LAB||||||10001|||50RC|SC|^BYME|2469^CLINIDATA||IPT
Q1 | 1 | 1 ^ Un | | | | 2023 09 15 16 29 08 0BR | 1 | ^ BYME | 24 69 ^ CLINIDATA | 93 ^ UREA
NITROGEN^CLINIDATA|||20230915162908SPM|1|||SERUM^SORO||||||||||
   CREATING ANALYSES
4.7
MSH|^~\&|LABENTERPRISEB|HCHTMAD|LABENTERPRISE|HCHTMAD|20220923112933||OML^021^0ML 021|e19941cf-805d-4f80-abe9-
329fb86871d9|P|2.5||||AL|
PID|1||187139^^^HCHTMAD^NS||ONE^TEST^||19870612|M|||^^^^||^^^^Telephone~~222^^^^^^Mobile|||||13003304|
ORC|NW|0478561-01^BHEALTH|^LABENTERPRISE|0478561||||20220923112933|||27837^ASUNCION
|| || |
SPM|1|||GEN^Product gen\XE9\rich|||||||
   CANCELLATION OF ANALYSES
4.8
MSH|^~\&|LABENTERPRISEB|HCHTMAD|LABENTERPRISE|HCHTMAD|20220923112858||OML^021^0ML_021|a04d4198-11c6-40e1-9e8c-
a258222a747f|P|2.5||||AL|
ORC|CA|0478535-02^BHEALTH|^LABENTERPRISE|0478535|||||20220923112858|||53886^AISSATO ABDU
IIIII
SPM 1 | | | GEN^Product gen\XE9\rich|| | | | | | |
4.9
   SCHEDULING
MSH|~~\&|LABENTERPRISEB|HCHTMAD|LABENTERPRISE|HCHTMAD|20220923113010||SIU^S12^SIU_S12|645157c6-5d69-4e42-aad5-
54cf493cd4c4|P|2.5
SCH | 0478561-
PV1|1|CON|||||||20092|||||||15054818
RGS 1 The
AIS|1|A|||||||BOOKED
AIL|1|A|ANALYS^Test Room An\XE1\lises|||20220923112931||||||BOOKED
AIP | 1 | A | |
   RESCHEDULE
33de443a70be | P | 2.5
SCH | 0478327-
PID | 1 | 187139^^^HDFF^NS | | ONE^TEST^ | | 19870612 | M | | | | | | | | | 13003304
PV1 1 CON | | | | | | | 20092 | | | | | | | | | 12345
RGS | 1 | S
AIL | 1 | S | ANALYS^Test Room An\XE1\lises | | | 20220922173000 | | | | | | BOOKED
AIP|1|S||
```

4.11 APPOINTMENT CANCELLATION

```
MSH|^~\&|LABENTERPRISEB|HCHTMAD|LABENTERPRISE|HCHTMAD|20220922160743||SIU^S15^SIU S15|fafc58c1-3cf3-43c5-9ebe-
2e12b9bd581d|P|2.5
SCH | 0478327-
PID|1||187139^^^HDFF^NS||ONE^TEST^||19870612|M|||||||13003304
PV1 | 1 | CON | | | | | | | | | 20092 | | | | | | | | | | | 12345
RGS | 1 | D
AIS 1 D | | | | | | | | CANCELLED
AIL|1|D|ANALYS^Test Room An\XE1\lises|||20220922170000||||||CANCELLED
AIP | 1 | D | |
4.12 ADMISSION/EFFECTIVENESS
MSH|^~\&|LABENTERPRISEB|HCHTMAD|LABENTERPRISE|HCHTMAD|20220923113011||OML^021^0ML_021|af079508-4ec2-4917-bf7c-
33cda049d979|P|2.5||||AL|
PID|1||187139^^^HCHTMAD^NS||ONE^TEST^||19870612|M|||^^^^||^^^^Telephone~~222^^^^^^Mobile||||13003304|
OBR|1|0478561-01^BHEALTH|^LABENTERPRISE|90^Albumin||20220923112829|||||||Test
SPM 1 | | | GEN^Product gen\XE9\rich | | | | | | | | |
4.13
    SAMPLE
MSH|^~\&|LABENTERPRISEB|HCHTMAD|LABENTERPRISE|HCHTMAD|20220923113325||OML^021^OML 021|1a269bde-ba81-4490-be38-
6e9ce1bb8c24|P|2.5||||AL|
ORC|SC|0478561-02^BHEALTH|^LABENTERPRISE|0478561|HD|||20220923113325|BM002^Francisco Zenha||27837^ASUNCION
SPM|1|||GEN^Product gen\XE9\rich|||||||
4.14
     CANCELLATION OF ANALYSES
MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923125325||OML^021^0ML 021|3015|P|2.5|||AL
PID|1||274797^^^SPMS^NS||ONE^TEST^THIRTY^^^^L||19860404000000||M|||||||||||^^SPMS
PV1 | 1 | URG | | | | | | | | 7429 | 10009 | | | | | | | | | | | 18051144
ORC|CA|0478536-02^LABENTERPRISEB|1980^LABENTERPRISE|0478536|CA|||||||||||...
TQ1|1|1^Un||||
OBR | 1 | 0478536-02^LABENTERPRISEB | 1980^LABENTERPRISE | 113^CALCIO^LABENTERPRISE | 20220923125325 |
SPM|1|||GEN^Gen\XE9\rich|||||||
4.15 VALIDATED ANALYSIS REPORT
MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923124420||OML^021^0ML_021|3006|P|2.5|||AL
PID|1||187139^^^SPMS^NS||A^TEST^^^^L||19870612000000|M||||||||13003304^^^SPMS
PV1|1|CON||||||27837|20092||||||||15054818
```

```
ORC | SC | 0478561-02^LABENTERPRISEB | 1982^LABENTERPRISE | 0478561 | CM | | | | | |
TQ1|1|1^Un||||20220923114030
OBR | 1 | 0478561 - 02^LABENTERPRISEB | 1982^LABENTERPRISE | 113^CALCIO^LABENTERPRISE | | | 20220923114030
SPM|1|||GEN^Gen\XE9\rich|||||||
```

4.16 ANALYSIS IN PROCESSING

```
 \begin{tabular}{ll} MSH|^-\&\|LABENTERPRISE|CHTMAD|20220923124045||OML^021^0ML_021|3002|P|2.5|||ALPID|1||187139^^SPMS^NS||A^TEST^^^^L||19870612000000|M||||||||13003304^^SPMS \\ \end{tabular}
PV1|1|CON||||||27837|20092||||||||15054818
ORC|SC|^LABENTERPRISEB|1983^LABENTERPRISE|0478561|IP|||||||
TQ1|1|1^Un||||20220923114030
OBR | 1 | ^LABENTERPRISEB | 1983 ^ LABENTERPRISE | 3 ^ HEMOGRAMA ^ LABENTERPRISE | | | 20220923114030
SPM|1|||GEN^Gen\XE9\rich|||||||
```

4.17 SIMPLE ANALYTICAL RESULTS

MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923124421||ORU^R01^ORU R01|3007|P|2.5|||AL PID|1||187139^^^SPMS^NS||A^TEST^^^^L||19870612000000|M||||||||13003304^^^SPMS

```
PV1|1|CON||||||27837|20092||||||||15054818
SPM|1|||GEN^Gen\XE9\rich|||||||
OBR | 1 | 0478561-02^LABENTERPRISEB | 1982^LABENTERPRISE | 113^CALCIO^LABENTERPRISE | | 20220923122400 | 20220923114030
ORC|SC|0478561-02^LABENTERPRISEB|1982^LABENTERPRISE|0478561|CM||||||
TQ1|1|1^Un||||20220923114030
OBX | 1 | NM | 1473 ^ C \ XC1 \ LCIO ^ LAB | | 12.0 | mg / dL | 8.8 - 10.2 | H | | | F | | | | 20220923114030 | | 8844
         ANALYTICAL RESULTS WITH MICROORGANISMS
MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923124420||ORU^R01^ORU_R01|3005|P|2.5|||AL
PID|1||187139^^^SPMS^NS||A^TEST^^^^L||19870612000000|M||||||||13003304^^^SPMS
PV1|1|CON|||||27837|20092|||||||15054818
SPM|1|||GEN^Gen\XE9\rich||||||
OBR|1|^LABENTERPRISEB|1983^LABENTERPRISE|3^HEMOGRAMA^LABENTERPRISE||20220923122400|20220923114030
ORC|SC|^LABENTERPRISEB|1983^LABENTERPRISE|0478561|CM||||||
TQ1|1|1^Un||||20220923114030
OBX|1|NM|3211^LEUC\XD3\CITOS^LAB||1.00|x10\XB3\/ul|4.00-10.50|L|||F|||20220923114030||8844
OBX|2|NM|3212^Neutr\XF3\filos:^LAB||1.3|%|1.5-6.6|L|||F|||20220923114030||8844
OBX|3|NM|25032^Neutr\XF3\phyla:^LAB||0.01|x10\XB3\/\XB5\L|1.50-6.60|L|||F|||20220923114030||8844

OBX|4|NM|3213^Lymph\XF3\cytos:^LAB||1.0|%|1.5-3.5|L|||F|||20220923114030||8844
OBX|5|NM|25024^Lymph\XF3\cytos:^LAB||0.01|x10\XB3\/\XB5\L|1.50-3.50|L|||F|||20220923114030||8844
OBX|6|NM|3388^Mon\XF3\cytos:^LAB||2.0|%|<1|H|||F|||20220923114030||8844
OBX|7|NM|25016^Mon\XF3\cytos:^LAB||0.02|x10\XB3\/\XB5\L|<1||||F||20220923114030||8844
OBX|8|NM|3386^Eosin\XF3\phyla:^LAB||3.0|%|<0.7|H||F||20220923114030||8844
OBX|9|NM|25008^Eosin\XF3\phyla:^LAB||0.03|x10\XB3\/\XB5\L|<0.7|||F|||20220923114030||8844
OBX|10|NM|3387^Bas\XF3\filos:^LAB||4.0|%|<0.1 .|A|||F|||20220923114030||8844
OBX 11 NM 25034^Bas\XF3\phyla:^LAB | 0.04 | x10\XB3\/\XB5\L|<0.1 .||||F|||20220923114030||8844
OBX|12|FT|3395^Observe\XE7\\XF5\es:^LAB||5|||||F|||20220923114030||8844
OBX|15|NM|3206^VGM:^LAB||8.0|fL|78.0-100.0|L|||F|||20220923114030||8844
OBX|16|NM|3208^CHGM:^LAB||9.0|g/dL|32.0-36.0|L|||F|||20220923114030||8844
OBX|17|NM|3379^RDW:^LAB||0.0|%|11.5-14.0|L|||F|||20220923114030||8844

OBX|18|FT|16716^erythroblasts:^LAB||0.0|%|||||F|||20220923114030||8844
OBX 19 NM 3224 PLATELETS LAB | 1 | x10 \ XB3 \ / \ XB5 \ L | 150 - 450 | L | | | F | | | 20220923114030 | | 8844
OBX|20|FT|3390^Observe\XE7\\XF5\es:^LAB||Thrombocytosis and giant platelets |||||F|||20220923114030||8844
OBX|21|FT|17707^OBSERVE \setminus XC3 \setminus EENERAL: \land LAB||Thrombocytosis \ and \ giant \ platelets
|||||||||||20220923114030||8844
        SAMPLE RETURN WITH LABEL
4.19
MSH|^{\sim} \& LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923125311||ORR^0002^{ORR}_002|3014|P|2.5|||ALRONOME | ALRONOME | ALRONO
PID|1|274797^^SPMS^NS||0NE^TEST^THIRTY^^^L||19860404000000|M|||||||||^^^SPMS
PV1|1|URG|||||7429|10009|||||||18051144
ORC | OK | 0478536-02^LABENTERPRISEB | 1980^LABENTERPRISE | 0478536 | | | | | | | | | | | | | | | |
OBR | 1 | 0478536-
Z01|1|1|CgpOCkE3MiwxMzY...
        SENDING THE PDF WITH THE RESULTS
4.20
MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923141053||ORU^R01^ORU_R01|3008|P|2.5|||AL
PID|1||187139^^^SPMS^NS||A^TEST^^^^L||19870612000000|M||||||||13003304^^^SPMS
PV1 1 CON | | | | | | | 20092 | | | | | | | | | 15054818
OBR 1 | ^LABENTERPRISEB | 1983^LABENTERPRISE | 3^HEMOGRAMA^LABENTERPRISE | 20220923122400 | 20220923114030
OBR 2 0478561-01^LABENTERPRISEB 1981^LABENTERPRISE 90^ALBUMIN^LABENTERPRISE 20220923122400 20220923114030
ORC|SC|0478561-
OBR | 3 | 0478561-02^LABENTERPRISEB | 1982^LABENTERPRISE | 113^CALCIO^LABENTERPRISE | | 20220923122400 | 20220923114030
ORC|SC|0478561-
OBX 1 | | | | ^^PDF^Base64^JVBER...
4.21
          DISABLING SCANS
MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923142750||MFN^Z01^MFN_Z01|3016|P|2.5||||AL
MFI LAB UPD
MFE | DCM | | | 138B
```

4.22 ENABLING ANALYTICS

 $\label{labenterprise} $$MSH^*_{a} = \frac{CHTMAD}LABENTERPRISEBCHTMAD^20220923142915\|MFN^*Z01^*MFN_Z01^*MFN_Z01^*BC1^*P^2.5\|\|ALMFI\|LAB\|UPD$$$

MFE|MAC|||138B

4.23 INSERTION OF ANALYSES

 $MSH|^{\sim}\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923143205||MFN^{2}01^{MFN}_{2}01|3018|P|2.5||||ALMFI|LAB|UPD \\ MFE|MAD|||56B \\ Z01|ANALYSIS|56B^{UREA} IN URINE 12H|5^{CLINICAL} CHEMISTRY|22^{Urine} Chemistry|7200|20$

4.24 ANALYTICS UPDATE

MSH|^~\&|LABENTERPRISE|CHTMAD|LABENTERPRISEB|CHTMAD|20220923150705||MFN^Z01^MFN_Z01|3025|P|2.5||||AL MFI|LAB|UPD MFE|MUP|||56A
Z01|ANALYSIS|56A^UREA UREA 12H|5^CLINICAL CHEMISTRY|22^Urine Chemistry|7200|20
Z02|INSTCOLH|5^^\X0D\\X0A\Collect blood without preparation\XE7\\XE3\o for creatinine assay.Z02|INFADIC|3^^Urine Volume 24h

5 REFERENCES AND ACTIONS

In the document we should standardize the designations based on "The Healthcare Simulation Dictionary" of the Society for Simulation in Healthcare (SSH) and Agency for Healthcare Research and Quality (AHRQ)